<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02029001</url>
  </required_header>
  <id_info>
    <org_study_id>ET12-081</org_study_id>
    <secondary_id>2012-004510-34</secondary_id>
    <nct_id>NCT02029001</nct_id>
  </id_info>
  <brief_title>Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: My Own Specific Treatment</brief_title>
  <acronym>MOST</acronym>
  <official_title>A Two-period, Multicenter, Randomized, Open-label, Phase II Study Evaluating the Clinical Benefit of a Maintenance Treatment Targeting Tumor Molecular Alterations in Patients With Progressive Locally-advanced or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Leon Berard</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Leon Berard</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      MOST is a phase II trial conducted in adult patients with an advanced solid tumor in
      progression after at least 1 prior treatment regimen. The study aims to assess whether a
      12-week treatment with a targeted therapy selected based on the alteration(s) detected in the
      tumor is sufficient to stabilize the disease compared with a longer treatment, for all
      patients presenting this alteration, regardless of the primary disease site or cancer type.
      All the targeted therapies administered in MOST study already obtained a marketing
      authorization (MA) but will be evaluated in indications other than those defined in their MA.

      Each patient enrolled will receive the matching targeted therapy during 12 weeks (induction
      treatment). At the end of this period:

        -  patients with a tumor response will continue the targeted therapy,

        -  patients in progression will discontinue the targeted therapy and will be withdrawn from
           study and oriented towards standard treatments

        -  patients with a stable disease at 12 weeks will be randomized in order to determine if
           they continue or stop the targeted therapy.

      About 80 patients will be treated in each of the 5 treatment groups opened to enrollment,
      each group corresponding to an available targeted therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>12-week Progression-Free Rate (12-week PFR)</measure>
    <time_frame>12 weeks after initiation of study treatment</time_frame>
    <description>the proportion of patients without documented disease progression within the first 12 weeks of study treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS) in both study arms after randomization</measure>
    <time_frame>tumor assessment every 2 to 3 months until up to 36 months after treatment start or patient's withdrawal</time_frame>
    <description>Measured from the date of randomization until the date of event defined as the first documented progression or death from any cause. Patients with no event at the time of the analysis will be censored at the date of the last available tumor assessment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Over the induction period</time_frame>
    <description>Proportion of patients with complete response (CR) or partial response (PR) according RECIST1.1 as best overall response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>from the date of randomization to the date of death from any cause</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's quality of life score (QLQ-C30) in both arms after randomization</measure>
    <time_frame>At randomization (week 12), week 28 and end of study for patient (week 136 or premature study withdrawal)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>Over the whole study</time_frame>
    <description>Type, frequency, seriousness and causality of adverse events reported from treatment initiation based on the common toxicity criteria grade (NCI CTC-AE-V4.03)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Duration of response (exploratory outcome)</measure>
    <time_frame>Over the whole study</time_frame>
    <description>Measured from the time of first documented response (CR or PR) until the first documented disease progression or death due to underlying cancer, and censored at the date of the last available tumor assessment</description>
  </other_outcome>
  <other_outcome>
    <measure>Medico-economic evaluation: cost analysis and cost-effectiveness analysis</measure>
    <time_frame>From randomization until patient's end of study</time_frame>
    <description>Incremental cost-effectiveness ratios (ICERs) will be expressed as:
the cost per life year gained;
the cost per progression-free year gained.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">560</enrollment>
  <condition>Malignant Solid Neoplasms</condition>
  <arm_group>
    <arm_group_label>Arm A: Maintenance treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will continue targeted treatment matching the molecular alterations identified in their tumor for a maximum of 136 weeks starting from the date of patient's first study drug intake following inclusion. In case of on-treatment disease progression, the patient will permanently discontinue treatment and will be withdrawn from study.
Targeted treatments available in the study are: nilotinib, everolimus, sorafenib, lapatinib and pazopanib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B:Interruption of targeted treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Targeted treatment received during induction period will be discontinued until a first radiologically-documented off-treatment disease progression occurs (according to RECIST 1.1). At progression, treatment reintroduction may be proposed to the patient (left at the investigator's appreciation, and upon patient approval) and treatment may be continued until on-treatment disease progression, unacceptable toxicity or for a maximum of 136 weeks from the date of patient's first study drug intake following inclusion. If the investigator considers that the treatment cannot be safely reintroduced (regarding patient's condition and/or laboratory results), the patient will be withdrawn from study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nilotinib (400 mg BID)</intervention_name>
    <description>Patients whose tumor harbors mutations of ABL1, KIT, PDGFRA, PDGFRB, DDR1, DDR2, CSF1R, or amplification/translocation of the genes and/or of the ligands.</description>
    <arm_group_label>Arm A: Maintenance treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus (10 mg QD)</intervention_name>
    <description>Patients whose tumor harbors mutations or amplification of the PIK3CA, PIK3R1, AKT1, AKT2, mTOR genes, or with TSC1, TSC2 or PTEN loss (defined as complete loss of both gene copies OR loss of one copy + mutation on the other copy).</description>
    <arm_group_label>Arm A: Maintenance treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib (400 mg BID)</intervention_name>
    <description>Patients whose tumor harbors mutations of VEGFR1-3, PDFGRB, FLT3, BRAF (other than V600 mutations), CRAF, KRAS or RET or amplification/translocation of the genes and/or of the ligands.</description>
    <arm_group_label>Arm A: Maintenance treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lapatinib (1500 mg QD)</intervention_name>
    <description>Patients whose tumor harbors mutations or amplifications of HER2</description>
    <arm_group_label>Arm A: Maintenance treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pazopanib (800 mg QD)</intervention_name>
    <description>Patients whose tumor harbors mutations of VEGFR1-3, PDGFRA, PDGFRB or KIT* or amplification /translocation of the genes and/or of the ligands.</description>
    <arm_group_label>Arm A: Maintenance treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        I1. Male or female patient ≥ 18 years of age I2. Histologically or cytologically confirmed
        diagnosis of metastatic or locally advanced and unresectable solid tumor of any type, not
        amenable to curative treatment. Concerning primitive tumors of the central nervous system
        (CNS), all histological types of malignant tumors (including parenchymal and meningeal
        tumors) are eligible.

        I3. Documented disease progression at the time of study entry. I4. At least one prior
        systemic treatment regimen for locally advanced or metastatic disease. Patients who are
        candidates for a validated second line treatment regimen are not eligible for the study.
        For patients with a primitive CNS tumor, the absence of other therapeutic options must be
        validated by the reference committee for the patient's pathology before inclusion. As there
        is no prior systemic treatment regimen available for locally advanced or metastatic PEComa,
        these tumors are eligible for a MTT treatment in first line of their advanced or metastatic
        disease I5. Patient with measurable disease, defined as at least one lesion that can be
        accurately measured on CT-scan or MRI according to RECIST 1.1 I6. A multidisciplinary
        molecular board must have recommended one of the investigational MTT available in the study
        after review of a tumor molecular profiling previously established from a biopsied lesion
        and/or primitive tumor.

        I7. The MTT recommended by the multidisciplinary molecular board after the review of tumor
        molecular profile is not approved and reimbursed in France for the disease affecting the
        patient.

        I8. ECOG performance status 0, 1 or 2

        I9. Adequate organ system function as assessed by the following minimal laboratory
        requirements :

          -  ANC ≥ 1 x 109/L (for pazopanib: ≥ 1.5 x 109/L)

          -  Platelets ≥ 100 x 109/L

          -  Hemoglobin ≥ 9 g/dL. Transfusion is not allowed within 7 days of screening assessment.

          -  For pazopanib: aPTT ≤ 1.2x ULN and PT or INR ≤ 1.2x ULN; Subjects receiving
             anticoagulant therapy are eligible if their INR is stable and within the recommended
             range for the desired level of anticoagulation.

          -  AST and ALT ≤ 3x ULN in the absence of liver metastases (≤ 5x ULN for patients with
             liver involvement of their cancer) and total bilirubin ≤ 1.5x ULN. (for pazopanib: AST
             and ALT ≤ 2.5x ULN; concomitant elevations in bilirubin and AST or ALT above 1x ULN
             are not permitted).

          -  Serum creatinine ≤ 1.5x ULN or creatinine clearance ≥ 50 mL/min (calculated by
             Cockcroft-Gault formula, or MDRD formula for patients older than 65 years) (for
             pazopanib: creatinine clearance ≥ 30 mL/min)

          -  For pazopanib: Urine Protein to Creatinine ratio (UPC) &lt;1; if UPC ≥1, 24-hour urine
             protein must be &lt;1g (use of urine dipstick for renal function assessment is not
             acceptable).

          -  Corrected QT interval ≤ 450 msecs (≤ 480 msecs if recommended MTT has no known effect
             on QT interval) on screening ECG, within 14 days prior to C1D1 I10. Life expectancy of
             at least 4 months I11. Specific toxicities related to any prior anti-cancer therapy
             must have resolved to grade ≤1 except for alopecia and fatigue. Grade 2 neutropenia or
             anemia is accepted.

        I12. Women of childbearing potential must have a negative pregnancy test performed within 3
        days prior to study treatment start. A positive urine test must be confirmed by a serum
        pregnancy test.

        I13. Women of childbearing potential (entering the study after a confirmed menstrual period
        and who have a negative pregnancy test) and men of reproductive potential must agree, if
        sexually active, to use two methods of medically acceptable forms of contraception during
        the study and for at least 8 weeks following the last treatment intake.

        I14. Signed and dated informed consent document indicating that the patient has been
        informed of all the pertinent aspects of the trial prior to enrollment.

        I15. The patient must be affiliated to the French social security system.

        Exclusion Criteria:

        Patients eligible for this study must not meet any of the following criteria:

        E1. Previous treatment in advanced phase with a targeted therapy inhibiting the same target
        proteins as this recommended for the study.

        E2. Any contra-indication to receive the recommended MTT, including known or suspected
        hypersensitivity to compounds of similar chemical or biologic composition as the active
        substance, or to any of the excipients.

        E3. For nilotinib, sorafenib, pazopanib and lapatinib: Patient with hypokalemia or known
        history of congenital long QT syndrome (QT interval prolongation).

        E4. Prior malignancy or presence of any other active malignancy. Subjects who have had
        another malignancy and have been disease-free for 5 years, or subjects with a history of
        completely resected non-melanomatous skin carcinoma or successfully treated in situ
        carcinoma are eligible.

        E5. Patient who have had major surgery or trauma within 28 days prior to first dose of
        investigational product.

        E6. Patient with symptomatic CNS metastatic involvement of his/her cancer, unless the
        patient have stable neurological function without evidence of CNS progression within 12
        weeks prior to study entry and does not require treatment with enzyme-inducing
        anticonvulsants or steroids. Patients with a primitive tumor of the CNS are not eligible if
        one of the following conditions is fulfilled:

          -  Alteration of cognitive functions impeding the patient's comprehension of study and
             the provision of informed consent by the patient himself/herself.

          -  Need for supportive care treatment(s) interfering with study treatment. E7. Treatment
             with any of the following anti-cancer therapies prior to the first dose of study
             treatment: radiation therapy, surgery or tumor embolization within 14 days prior to
             the first dose of study treatment OR immunotherapy within 28 days OR chemotherapy,
             biologic therapy, investigational therapy or hormonal therapy within 14 days or 5
             half-lives of a drug (whichever is longer). Palliative radiotherapy is authorized only
             if the irradiated field does not include target lesions.

        E8. Administration of any non-oncologic investigational agent within 30 days or 5
        half-lives (whichever is longer) prior to receiving the first dose of study treatment.

        E9. Patient with any condition that impairs their ability to swallow and retain tablets and
        may affect the absorption of the investigational product are excluded.

        E10. For pazopanib: Clinically significant gastrointestinal abnormalities that may increase
        the risk for gastrointestinal bleeding including, but not limited to:

          -  Active peptic ulcer disease

          -  Known intraluminal metastatic lesion(s) with risk of bleeding

          -  Inflammatory bowel disease or other gastrointestinal conditions with increased risk of
             perforation

          -  History of abdominal fistula, gastrointestinal perforation, or intra abdominal abscess
             within 28 days prior to beginning study treatment.

        E11. For pazopanib: Evidence of active bleeding or bleeding diathesis. E12. For pazopanib:
        Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels that
        increase the risk of pulmonary hemorrhage.

          -  Lesions infiltrating major pulmonary vessels (contiguous tumour and vessels) are
             excluded; however, the presence of a tumor that is touching, but not infiltrating
             (abutting) the vessels is acceptable.

          -  Large protruding endobronchial lesions in the main or lobar bronchi are excluded;
             however, endobronchial lesions in the segmented bronchi are allowed.

          -  Lesions extensively infiltrating the main or lobar bronchi are excluded; however,
             minor infiltrations in the wall of the bronchi are allowed.

        E13. For pazopanib: Recent hemoptysis.

        E14. Any clinically significant and/or uncontrolled medical disease that could compromise
        the patient's ability to tolerate study treatment or would likely interfere with study
        procedures or results. These conditions include but are not limited to:

          -  Active clinically serious bacterial or fungal infection

          -  History of uncontrolled or significant cardiac disease within the past 6 months: LVEF
             &lt; 50%, congestive cardiac failure, active ischemic heart disease, ventricular
             arrhythmia, myocardial infarction within 1 year, unstable angina pectoris, cardiac
             surgery.

          -  Patients with cerebrovascular accident (including transient ischemic attack),
             pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months
             are not eligible for pazopanib treatment group

          -  Poorly controlled hypertension [for pazopanib: defined as systolic blood pressure
             (SBP) ≥140 mmHg or diastolic blood pressure (DBP) ≥ 90mmHg]

          -  Severely impaired lung function

          -  Active gastrointestinal tract ulceration

          -  Acute or chronic uncontrolled liver disease, or severe renal disease

          -  Uncontrolled diabetes

          -  Known history of HIV infection, or active viral infection (HBV, HCV) at the time of
             study entry and/or requiring anti-viral therapy, or chronic hepatitis B or C.
             Detection of hepatitis C RNA must be performed before inclusion of patients with a
             history of HCV infection: patients with a positive result are excluded.

          -  History of organ allograft or patient taking immunosuppressive treatment E15. Patient
             unable or unwilling to discontinue use of prohibited medications for at least 14 days
             or 5 half-lives of a drug (whichever is longer) prior to the first dose of study drug
             and for the duration of the study.

        E16. Pregnant or breastfeeding women. E17. Patients with any medical, psychological,
        familial, sociological or geographical condition potentially hampering compliance with the
        study protocol and follow-up schedule or evaluations of the study results.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Yves BLAY, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Leon Berard</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Yves BLAY, MD</last_name>
    <phone>+33478785126</phone>
    <email>jean-yves.blay@lyon.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Olivier TREDAN, MD</last_name>
    <phone>+33478782828</phone>
    <email>olivier.tredan@lyon.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine ITALIANO</last_name>
      <phone>+335 56 33 33 33</phone>
      <email>a.italiano@bordeaux.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Antoine ITALIANO</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Delphine GARBAY</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maud TOULMONDE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie COUSIN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sylvestre LE MOULEC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xavier DURANDO</last_name>
      <phone>04 73 27 81 31</phone>
      <email>xavier.durando@cjp.fr</email>
    </contact>
    <investigator>
      <last_name>Xavier DURANDO</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre DALLOZ</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne-Françoise DILLIES-LEGRAIN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pascale DUBRAY-LONGERAS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hakim MAHAMMEDI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie-Ange MOURET-REYNIER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabelle VAN PRAAGH DOREAU</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Daniel Hollard</name>
      <address>
        <city>Grenoble</city>
        <zip>38028</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cécile LEYRONNAS</last_name>
      <phone>04 76 70 73 33</phone>
      <email>c.leyronnas@ghm-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Cécile LEYRONNAS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claire GARNIER-TIXIDRE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurence LANCRY-LECOMTE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jérôme LONG, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christine REBISCHUNG, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Yves BLAY</last_name>
      <phone>+33478785126</phone>
      <email>jean-yves.blay@lyon.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Yves BLAY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Virginie AVRILLON</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas BACHELOT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christophe BERGERON</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre BIRON</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Helen BOYLE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe CASSIER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrick COMBEMALE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria CHELGHOUM</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Françoise DESSEIGNE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cécile FAURE-CONTER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jérome FAYETTE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aude FLECHON</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christelle DE LA FOUCHARDIERE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Didier FRAPPAZ</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre GUIBERT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre-Etienne HEUDEL</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alice LEVARD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sylvie NEGRIER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eve-Marie NEIDHARDT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maurice PEROL</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabelle RAY-COQUARD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul REBATTU</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre SAINTIGNY</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Catherine TERRET</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier TREDAN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivia BALLY</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stéphane DEPIL</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olfa DERBEL</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nathalie MARQUES</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe TOUSSAINT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mehdi BRAHMI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthieu SARABI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julien FORESTIER, MD</last_name>
      <phone>+33472119738</phone>
      <email>julien.forestier@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Julien FORESTIER</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Catherine LOMBARD BOHAS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas WALTER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yann MOLIN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Noura BEN SLAMA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François BERTUCCI</last_name>
      <phone>+334 91 22 35 37</phone>
      <email>bertuccif@ipc.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>François BERTUCCI</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Marc EXTRA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anthony GONCALVES</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gwenaêlle GRAVIS-MESCAM</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne MADROSZYK-FLANDIN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Luc RAOUL</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Delphine PERROT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Magali PROVENSAL</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carole TARPIN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frédéric VIRET</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Louis TASSY</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75248</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe LE TOURNEAU, MD</last_name>
      <phone>+33144324672</phone>
      <email>Christophe.letourneau@curie.fr</email>
    </contact>
    <investigator>
      <last_name>Christophe LE TOURNEAU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe BEUZEBOC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>François-Clément BIDARD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bruno BUECHER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul-Henri COTTU</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Catherine DANIEL</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Véronique DIERAS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Valérie LAURENCE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alain LIVARTOWSKI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Yves PIERGA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie ALT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Delphine LOIRAT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie-Paule SABLIN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mustapha ZOUBIR</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francesco RICCI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benoit YOU, MD</last_name>
      <phone>+33478864319</phone>
      <email>benoit.you@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Benoit YOU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nathalie BONNIN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gilles FREYER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Salima HAMIZI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie TARTAS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Véronique TRILLET-LENOIR</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marion CHAUVENET</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Denis MAILLET</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julien PERON</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de cancérologie LUCIEN NEUWIRTH</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier COLLARD, MD</last_name>
      <phone>04 77 91 70 34</phone>
      <email>olivier.collard@icloire.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier COLLARD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claire BOSACKI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre FOURNEL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aline GUILLOT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Philippe JACQUIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thierry MURON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Léa SABAN-ROCHE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos-Alberto GOMEZ-ROCA</last_name>
      <phone>05 31 15 51 01</phone>
      <email>Gomez-roca.carlos@iuct-oncopole.fr</email>
    </contact>
    <investigator>
      <last_name>Carlos-Alberto GOMEZ-ROCA</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christine CHEVREAU</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ewa-Anna COTTURA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Florence DALENC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Pierre DELORD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marion DESLANDRES</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cécile GANDY</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurence GLADIEFF</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eleonora MAIO D'ESPOSITO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas MEYER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Loïc MOUREY</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elisabeth MOYAL</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Henri ROCHE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thibaud VALENTIN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sarah ZAHI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roxana Maria RADUT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.cancer-lyric.com/en/</url>
    <description>MOST study is part of the LyRIC project, click here to access LyRIC website</description>
  </link>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2014</study_first_submitted>
  <study_first_submitted_qc>January 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2014</study_first_posted>
  <last_update_submitted>January 26, 2018</last_update_submitted>
  <last_update_submitted_qc>January 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solid tumor</keyword>
  <keyword>Recurrent/metastatic</keyword>
  <keyword>Personalized medicine</keyword>
  <keyword>Genomic alteration</keyword>
  <keyword>Targeted therapy</keyword>
  <keyword>Nilotinib</keyword>
  <keyword>Everolimus</keyword>
  <keyword>Sorafenib</keyword>
  <keyword>Lapatinib</keyword>
  <keyword>Pazopanib</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Lapatinib</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

